Marinas Ainhoa, Villanueva Vicente, Giráldez Beatriz G, Molins Albert, Salas-Puig Javier, Serratosa Jose M
Fundación Jiménez Díaz, Madrid, Spain.
Epileptic Disord. 2009 Mar;11(1):61-6. doi: 10.1684/epd.2009.0239. Epub 2009 Mar 5.
The objective of this study is to evaluate the efficacy and safety of zonisamide (ZNS) for the treatment of idiopathic generalized epilepsies (IGEs).
Thirteen patients with different types of IGEs who were treated with ZNS between the years 2006 and 2008 were identified. Efficacy and tolerability were assessed at months 6 and 12 post-treatment. Response was defined as a 50% or greater reduction in seizure frequency.
Twelve patients (92.3%) continued with ZNS at month 6, and 11 (84.6%) at month 12. Mean daily dose was 319 mg (range 100-500 mg/d). Response was achieved at month 6 in eight of the 12 patients that continued with ZNS (66.6%), of which 7 were seizure-free (58.3%). At month 12, eight of the 11 patients that continued with ZNS were responders (72.7%) and 6 were seizure-free (63.6%). For different types of seizures, better responses were observed for absences and generalized tonic-clonic seizures. Four out of 13 patients (30.7%) experienced adverse events and in two (15.3%), these led to withdrawal.
In this retrospective study, ZNS showed efficacy and tolerability for the treatment of different types of IGEs. Limitations include a small sample size and a relatively short period of follow-up. Our results are promising and justify the need for prospective controlled trials in IGE.
本研究旨在评估唑尼沙胺(ZNS)治疗特发性全身性癫痫(IGEs)的疗效和安全性。
确定了2006年至2008年间接受ZNS治疗的13例不同类型IGEs患者。在治疗后6个月和12个月评估疗效和耐受性。反应定义为癫痫发作频率降低50%或更多。
12例患者(92.3%)在6个月时继续使用ZNS,11例(84.6%)在12个月时继续使用。平均日剂量为319毫克(范围100 - 500毫克/天)。在继续使用ZNS的12例患者中,8例(66.6%)在6个月时达到反应,其中7例无癫痫发作(58.3%)。在12个月时,继续使用ZNS的11例患者中有8例(72.7%)有反应,6例(63.6%)无癫痫发作。对于不同类型的癫痫发作,失神发作和全身性强直 - 阵挛性发作的反应更好。13例患者中有4例(30.7%)出现不良事件,2例(15.3%)因这些不良事件而停药。
在这项回顾性研究中,ZNS对治疗不同类型的IGEs显示出疗效和耐受性。局限性包括样本量小和随访时间相对较短。我们的结果很有前景,证明有必要对IGEs进行前瞻性对照试验。